Jupiter Neurosciences, Inc. Common Stock Total Liabilities
Jupiter Neurosciences, Inc. Common Stock total liabilities. Based on the latest financial reports, Jupiter Neurosciences, Inc. Common Stock (JUNS) has total liabilities worth $4.08 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See JUNS defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Jupiter Neurosciences, Inc. Common Stock (2019–2025)
Total liabilities of Jupiter Neurosciences, Inc. Common Stock from 2019 to 2025. This chart illustrates how Jupiter Neurosciences, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data.
Jupiter Neurosciences, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Jupiter Neurosciences, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
8I Holdings Ltd
AU:8IH
|
Australia | AU$316.61K |
|
Dialight plc
LSE:DIA
|
UK | GBX54.20 Million |
|
WEBUY GLOBAL LTD. Ordinary Shares
NASDAQ:WBUY
|
USA | $12.89 Million |
|
Rubico Inc. Common Stock
NASDAQ:RUBI
|
USA | $99.32 Million |
|
Precomp Solutions AB Series B
ST:PCOM-B
|
Sweden | Skr72.30 Million |
|
Silver Wolf Exploration Ltd
V:SWLF
|
Canada | CA$513.59K |
|
Railway Metrics & Dynamics Sweden AB
ST:RMDX
|
Sweden | Skr44.64 Million |
|
Simble Solutions Ltd
AU:SIS
|
Australia | AU$1.22 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down Jupiter Neurosciences, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Jupiter Neurosciences, Inc. Common Stock.
Liquidity & Leverage Metrics
Jupiter Neurosciences, Inc. Common Stock Total Liabilities Ratios Explained
Jupiter Neurosciences, Inc. Common Stock total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.66 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -11.16 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Jupiter Neurosciences, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Jupiter Neurosciences, Inc. Common Stock (2019–2025)
The table below shows the annual total liabilities of Jupiter Neurosciences, Inc. Common Stock from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $7.40 Million | +264.26% |
| 2024-12-31 | $2.03 Million | -65.88% |
| 2023-12-31 | $5.95 Million | -19.38% |
| 2022-12-31 | $7.38 Million | +26.26% |
| 2021-12-31 | $5.85 Million | +37.18% |
| 2020-12-31 | $4.26 Million | -15.16% |
| 2019-12-31 | $5.02 Million | -- |
About Jupiter Neurosciences, Inc. Common Stock
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, engages in the development of therapeutics for central nervous system disorders and rare diseases in the United States and internationally. It operates in two segments, Pharmaceutical Operations and Premium Nutritional Supplements. The company researches and develops JNS115, which is in Phase IIa clinic… Read more